Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) Expected to Announce Quarterly Sales of $520,000.00

Wall Street brokerages expect Infinity Pharmaceuticals, Inc. (NASDAQ:INFIGet Rating) to post $520,000.00 in sales for the current quarter, according to Zacks. Three analysts have made estimates for Infinity Pharmaceuticals’ earnings, with the lowest sales estimate coming in at $200,000.00 and the highest estimate coming in at $680,000.00. Infinity Pharmaceuticals reported sales of $510,000.00 in the same quarter last year, which indicates a positive year-over-year growth rate of 2%. The business is scheduled to issue its next earnings report on Monday, January 1st.

According to Zacks, analysts expect that Infinity Pharmaceuticals will report full year sales of $2.05 million for the current year, with estimates ranging from $800,000.00 to $2.70 million. For the next year, analysts forecast that the company will report sales of $2.17 million, with estimates ranging from $800,000.00 to $3.00 million. Zacks’ sales calculations are a mean average based on a survey of research firms that that provide coverage for Infinity Pharmaceuticals.

Infinity Pharmaceuticals (NASDAQ:INFIGet Rating) last posted its quarterly earnings data on Tuesday, May 3rd. The biotechnology company reported ($0.14) EPS for the quarter, meeting the consensus estimate of ($0.14). Infinity Pharmaceuticals had a negative net margin of 2,254.97% and a negative return on equity of 175.11%. The business had revenue of $0.65 million during the quarter, compared to analyst estimates of $0.40 million. During the same quarter last year, the firm posted ($0.15) earnings per share.

Several research analysts have recently issued reports on INFI shares. Piper Sandler cut their price target on Infinity Pharmaceuticals from $4.00 to $3.00 and set an “overweight” rating for the company in a research note on Monday, May 23rd. Zacks Investment Research upgraded Infinity Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Tuesday, March 8th. Truist Financial reduced their target price on Infinity Pharmaceuticals from $12.00 to $4.00 and set a “buy” rating for the company in a research note on Thursday, March 31st. Finally, StockNews.com raised Infinity Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Sunday, May 15th. Two investment analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus price target of $6.25.

Several hedge funds have recently bought and sold shares of INFI. Citigroup Inc. increased its stake in shares of Infinity Pharmaceuticals by 141.7% in the 3rd quarter. Citigroup Inc. now owns 10,073 shares of the biotechnology company’s stock valued at $34,000 after purchasing an additional 5,906 shares during the last quarter. Mirabella Financial Services LLP bought a new position in shares of Infinity Pharmaceuticals in the 1st quarter worth about $34,000. Two Sigma Securities LLC bought a new position in shares of Infinity Pharmaceuticals in the 3rd quarter worth about $39,000. Bank of America Corp DE raised its position in shares of Infinity Pharmaceuticals by 178.3% in the 4th quarter. Bank of America Corp DE now owns 23,595 shares of the biotechnology company’s stock worth $53,000 after acquiring an additional 15,117 shares in the last quarter. Finally, BNP Paribas Arbitrage SA increased its position in Infinity Pharmaceuticals by 373.1% in the 3rd quarter. BNP Paribas Arbitrage SA now owns 15,947 shares of the biotechnology company’s stock valued at $55,000 after buying an additional 12,576 shares in the last quarter. 54.74% of the stock is owned by institutional investors.

NASDAQ:INFI traded up $0.15 during midday trading on Friday, reaching $0.75. The stock had a trading volume of 1,316,177 shares, compared to its average volume of 881,438. The firm has a fifty day simple moving average of $0.84 and a two-hundred day simple moving average of $1.38. Infinity Pharmaceuticals has a 12-month low of $0.46 and a 12-month high of $3.89. The stock has a market cap of $66.87 million, a P/E ratio of -1.44 and a beta of 2.16.

About Infinity Pharmaceuticals (Get Rating)

Infinity Pharmaceuticals, Inc, a biopharmaceutical company, focuses on developing novel medicines for people with cancer. Its product candidate is IPI-549, an orally administered clinical-stage immuno-oncology product candidate that inhibits the enzyme phosphoinositide-3-kinase-gamma, which is in Phase 2 clinical trials for the treatment of metastatic triple negative breast cancer and urothelial cancer; and Phase 1/1b clinical trials for the treatment of solid tumors.

Further Reading

Get a free copy of the Zacks research report on Infinity Pharmaceuticals (INFI)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Infinity Pharmaceuticals (NASDAQ:INFI)

Receive News & Ratings for Infinity Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Infinity Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.